Skip to main content

BioMedNewsBreaks — 180 Life Sciences Corp. (NASDAQ: ATNF) Appoints Omar Jimenez as Chief Financial Officer

180 Life Sciences (NASDAQ: ATNF) announced on Thursday its appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Jimenez, a current director of the Company, will leverage his extensive financial management experience to steer the Company’s growth and innovation in the pharmaceutical and biotechnology sectors. With a background that includes leadership roles in companies like Golden Matrix Group and Alfadan, Inc., Jimenez brings a wealth of expertise in financial reporting, management, and capital markets. He holds a BBA in Accounting and Finance from the University of Miami and an MBA in Finance & Management from Florida International University. The Company expressed gratitude to outgoing CFO Ozan Pamir for his contributions.

To view the full press release, visit https://ibn.fm/Jv4xr

About 180 Life Sciences Corp.

180 Life Sciences Corp. is a clinical stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy. For more information, visit the company’s website at www.180LifeSciences.com

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.